385 related articles for article (PubMed ID: 25837920)
1. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.
Li L; Li L; Chen L; Lin X; Xu Y; Ren J; Fu J; Qiu Y
J Pharmacol Sci; 2015 Mar; 127(3):244-50. PubMed ID: 25837920
[TBL] [Abstract][Full Text] [Related]
2. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
3. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
[TBL] [Abstract][Full Text] [Related]
4. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
5. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Fu J; Oveisi F; Gaetani S; Lin E; Piomelli D
Neuropharmacology; 2005 Jun; 48(8):1147-53. PubMed ID: 15910890
[TBL] [Abstract][Full Text] [Related]
6. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
[TBL] [Abstract][Full Text] [Related]
7. Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
Jiang S; Uddin MJ; Yu X; Piao L; Dorotea D; Oh GT; Ha H
Diabetes Metab J; 2022 Nov; 46(6):829-842. PubMed ID: 35746892
[TBL] [Abstract][Full Text] [Related]
8. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
9. Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour.
Sihag J; Jones PJH
Obes Rev; 2018 Feb; 19(2):178-197. PubMed ID: 29124885
[TBL] [Abstract][Full Text] [Related]
10. A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation.
An HJ; Lee B; Kim SM; Kim DH; Chung KW; Ha SG; Park KC; Park YJ; Kim SJ; Yun HY; Chun P; Yu BP; Moon HR; Chung HY
Biol Pharm Bull; 2018; 41(1):29-35. PubMed ID: 29311481
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity.
Tutunchi H; Saghafi-Asl M; Ostadrahimi A
Clin Exp Pharmacol Physiol; 2020 Apr; 47(4):543-552. PubMed ID: 31868943
[TBL] [Abstract][Full Text] [Related]
13. The effects of oleoylethanolamide, an endogenous PPAR-α agonist, on risk factors for NAFLD: A systematic review.
Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Maleki V
Obes Rev; 2019 Jul; 20(7):1057-1069. PubMed ID: 31111657
[TBL] [Abstract][Full Text] [Related]
14. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).
Guzmán M; Lo Verme J; Fu J; Oveisi F; Blázquez C; Piomelli D
J Biol Chem; 2004 Jul; 279(27):27849-54. PubMed ID: 15123613
[TBL] [Abstract][Full Text] [Related]
15. Nutritional background changes the hypolipidemic effects of fenofibrate in Nile tilapia (Oreochromis niloticus).
Ning LJ; He AY; Lu DL; Li JM; Qiao F; Li DL; Zhang ML; Chen LQ; Du ZY
Sci Rep; 2017 Jan; 7():41706. PubMed ID: 28139735
[TBL] [Abstract][Full Text] [Related]
16. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
Chang CJ; Tzeng TF; Liou SS; Chang YS; Liu IM
Planta Med; 2011 Nov; 77(17):1876-82. PubMed ID: 21728151
[TBL] [Abstract][Full Text] [Related]
17. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
[TBL] [Abstract][Full Text] [Related]
18. Vagal afferents are not necessary for the satiety effect of the gut lipid messenger oleoylethanolamide.
Azari EK; Ramachandran D; Weibel S; Arnold M; Romano A; Gaetani S; Langhans W; Mansouri A
Am J Physiol Regul Integr Comp Physiol; 2014 Jul; 307(2):R167-78. PubMed ID: 24829501
[TBL] [Abstract][Full Text] [Related]
19. Sake lees extract improves hepatic lipid accumulation in high fat diet-fed mice.
Kubo H; Hoshi M; Matsumoto T; Irie M; Oura S; Tsutsumi H; Hata Y; Yamamoto Y; Saito K
Lipids Health Dis; 2017 Jun; 16(1):106. PubMed ID: 28578672
[TBL] [Abstract][Full Text] [Related]
20. Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying mechanisms.
Zhang X; Zhang Y; Gao W; Guo Z; Wang K; Liu S; Duan Z; Chen Y
Life Sci; 2021 Jul; 277():119487. PubMed ID: 33862107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
